rs896947430
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PVS1PM2PP5
The NM_001378615.1(CC2D2A):c.100C>T(p.Arg34*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000174 in 1,554,006 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001378615.1 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CC2D2A | NM_001378615.1 | c.100C>T | p.Arg34* | stop_gained | 3/37 | ENST00000424120.6 | NP_001365544.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152118Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000617 AC: 1AN: 161988Hom.: 0 AF XY: 0.0000117 AC XY: 1AN XY: 85108
GnomAD4 exome AF: 0.0000171 AC: 24AN: 1401888Hom.: 0 Cov.: 30 AF XY: 0.0000159 AC XY: 11AN XY: 691664
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152118Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74296
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Jul 14, 2016 | - - |
Pathogenic, criteria provided, single submitter | research | Genomic Research Center, Shahid Beheshti University of Medical Sciences | Jan 01, 2019 | - - |
CC2D2A-related disorder Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | research | MUHC Nephrogenetics Laboratory, Research Institute of the McGill University Health Centre | Jun 14, 2024 | Genetic testing identified a homozygous nonsense variant in the gene CC2D2A: NM_001378615.1(CC2D2A):c.100C>T (p.Arg34Ter). The variant was classified as a variant of uncertain significance (VUS) by the clinical laboratory. It is extremely rare in the reference population and generates a premature stop codon in exon 3 of the canonical transcript (NM_001378615.1). Using in silico prediction tools, p.(Arg34*) is not expected to efficiently trigger NMD, nor completely escape NMD, suggesting a potential partial loss-of-function effect. Both predictive and in vitro models of the CC2D2A p.(Arg34*) nonsense variant suggest translation re-initiation may occur at the downstream translation initiation site, potentially recovering residual protein function. The region that is lost from the full-length CC2D2A protein isoform (amino acid residues 1-49) does not contain any annotated functional protein domains, nor does it contain any reported interaction sites or localization signals, suggesting the shorter protein may retain function. Transcript-isoform expression analysis revealed that this variant primarily affects kidney-predominant transcripts. We conclude that the reduction of the kidney enriched CC2D2A protein isoform may result in progressive and degenerative renal disease. ACMG Classification: The CC2D2A c.100C>T, p.(Arg34*) was classified as a variant of uncertain significance (VUS) because insufficient evidence existed to support its pathogenicity. Variant interpretation was performed based on the general recommendations from the Sequence Variant Interpretation (SVI) Working Group for using ACMG/AMP Criteria (Clinical Genome Resource). Population Data: The variant is extremely rare in a healthy population database (gnomAD v2.1.1); however, the patient has Cree ancestry, which is not represented in population databases; therefore, the variant frequency in Cree population is not known. Therefore, PM2 cannot be invoked. Computational & Predictive Data: Nonsense variant in the gene CC2D2A, predicted to cause NMD. Loss-of-function is a known mechanism of disease. Exons 1-3 are biologically relevant to kidney function. SVI Working Group reached a consensus agreement that removing >10% of the protein product is more likely to have a loss of function effect compared to variants that remove <10%. PVS1_Strong was therefore invoked according to the recommended guidelines. Other Databases: The variant has been reported on ClinVar as Pathogenic and Likely Pathogenic, but without phenotype information. PP5 was not invoked according to recommended guidelines. - |
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 12, 2024 | The CC2D2A c.100C>T variant is predicted to result in premature protein termination (p.Arg34*). To our knowledge, this variant has not been reported in individuals with CC2D2A-associated disorders in the literature or in a large population database, indicating this variant is rare. Nonsense variants in CC2D2A are expected to be pathogenic. This variant is interpreted as likely pathogenic. - |
Meckel-Gruber syndrome;C0431399:Familial aplasia of the vermis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | This sequence change creates a premature translational stop signal (p.Arg34*) in the CC2D2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CC2D2A are known to be pathogenic (PMID: 19777577). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CC2D2A-related conditions. ClinVar contains an entry for this variant (Variation ID: 377067). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at